Aurobindo Pharma in focus on launch of generic version of Sensipar tablets in US

Aurobindo Pharma's Cinacalcet Hydrochloride tablets 30mg, 60mg, and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets.

New Delhi: Drug maker Aurobindo Pharma Limited recently announced the launch of Cinacalcet Hydrochloride Tablets (30mg, 60mg, and 90mg) at risk in the US market in accordance with the terms of a settlement agreement with Amgen Inc.

Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg, and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets.

Also Read: Aurobindo Pharma, Dr Reddys, Torrent Pharma, Mylan cannot sell generic Gilenya patented by Novartis

Cinacalcet Hydrochloride tablets are indicated for the treatment of:

• Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKO) on dialysis
• Hypercalcemia in adult patients with parathyroid carcinoma
• Severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy

The product had an annual sale of approximately US$ 1,449 million for the twelve months ending May 2019 as per IQVIA.

Also Read: Aurobindo Pharma pulled up by USFDA for repeated CGMP failures